Humana Inc. (NYSE:HUM) stock climbed more than 3% Tuesday, outperforming the broader market as the health insurer announced a new cancer care initiative and investors assessed its recently raised earnings outlook.

The gains came as the Nasdaq fell 1.34% and the S&P 500 declined 0.78%. The health care sector slipped 0.07%, while technology stocks dropped 2.04%.

Humana Launches Cancer Care Model Across Eight States

On Tuesday, Humana announced a new cancer care model with Evolent Health Inc. (NYSE:EVH) and American Oncology Network (AON).

The program aims to improve cancer treatment while reducing administrative delays and reliance on traditional prior authorization.

The companies launched the initiative at AON clinics across eight states.

Under the model, participating providers who meet established treatment standards can bypass traditional prior authorization requests for most anticancer drug therapies.

Evolent will support the program through clinical pathways, quality improvement initiatives and provider performance reporting.

The initiative also uses real-time patient data to help physicians make treatment decisions.

Humana Raises 2026 Earnings Forecast

The announcement follows Humana's third-quarter results, released last week.

The insurer reported an adjusted loss of 70 cents per share, narrower than Wall Street's expected $1 loss.

Revenue climbed to $41.16 billion from $32.65 billion, beating the $40.89 billion estimate.

Humana raised its 2026 adjusted earnings forecast to at least $9.50 per share from at least $9.

The company also reported 18.04 million medical members, up from 14.99 million a year earlier.

Meanwhile, JPMorgan maintained a Neutral rating Tuesday and raised its price forecast to $484.

Piper Sandler and Guggenheim raised their price forecasts Monday to $526 and $521, respectively.

HUM Stock Technical Analysis

Humana shares have gained 83.39% over the past 12 months and remain above their major moving averages.

The stock trades above its 20-day simple moving average of $420.56 and its 200-day average of $313.64.

Its moving average convergence divergence (MACD) indicator remains above the signal line, suggesting positive momentum.

The stock faces resistance near its 52-week high of $456.50, while support stands around $407.50.

HUM Price Action: Humana shares were up 3.19% at $436.71 at the time of publication Tuesday, according to market data.